Most people assume semaglutide protects the heart because it helps people lose weight. A major prespecified analysis of the SELECT trial - published in The Lancet in October 2025 - shows that assumption is only partly right. And the part it gets wrong matters considerably.

What the SELECT trial was designed to answer

The SELECT trial enrolled 17,604 adults with overweight or obesity and pre-existing cardiovascular disease but without diabetes. Participants were randomised to weekly semaglutide 2.4 mg (the Wegovy dose) or placebo and followed for approximately four years across 804 sites in 41 countries. All participants had a BMI of at least 27 kg/m² and an established history of heart disease - previous heart attack, stroke, or peripheral arterial disease.

The primary question: does semaglutide reduce the incidence of major adverse cardiovascular events (MACE) - a composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death?

The headline answer, already known from the original trial publication, was yes: semaglutide reduced MACE incidence from 8.5% in the placebo group to 6.0% in the semaglutide group over the study period - a 20% relative risk reduction.

The prespecified analysis published in The Lancet on October 22, 2025, asked a more precise question: does the cardiovascular benefit depend on how much weight participants lost, or on their baseline body size? The answer rewrites a significant assumption about how semaglutide works.

The key finding: weight loss explains only one-third of the benefit

Across all analyses, semaglutide's cardiovascular protection was consistent regardless of how much weight a participant lost. Patients who lost very little weight - some losing under 5% of body weight - experienced comparable reductions in MACE to those who lost 15% or more.

When researchers used statistical mediation analysis to quantify how much of the benefit was attributable to changes in waist circumference (a marker of central adiposity), the answer was approximately one-third. About 33% of semaglutide's cardiovascular benefit could be explained by the reduction in body fat. The remaining two-thirds came from something else.

Professor Azeem Majeed of Imperial College London, commenting on the findings, described this as a "high-quality study" demonstrating that waist circumference reduction mediates "only about a third" of the MACE improvement - directly challenging the assumption that weight loss drives most of the cardiac benefit.

Professor Naveed Sattar of the University of Glasgow noted the findings align with what has been seen in diabetes trials, suggesting GLP-1 drugs have "direct effects on tissues that slow development of plaques" - a reference to atherosclerosis, the arterial plaque buildup that underlies most heart attacks and strokes.

What the other two-thirds might be

If weight loss accounts for roughly a third of the cardiovascular benefit, what drives the rest? Researchers have proposed several mechanisms that operate independently of fat reduction:

Anti-inflammatory effects

GLP-1 receptors are present in immune cells and arterial walls. Semaglutide appears to reduce systemic inflammation - including C-reactive protein (CRP) and other inflammatory markers elevated in cardiovascular disease. Atherosclerotic plaque is partly driven by chronic inflammation in artery walls; reducing inflammation may slow plaque progression regardless of body weight.

Direct effects on arterial function

GLP-1 receptor activation in endothelial cells (the cells lining blood vessels) improves nitric oxide availability, which regulates vasodilation - the ability of vessels to widen and improve blood flow. Impaired vasodilation is an early marker of cardiovascular disease. Semaglutide may improve endothelial function independently of weight change.

Blood pressure reduction

SELECT trial participants on semaglutide showed modest but consistent reductions in systolic blood pressure compared to placebo. Blood pressure reduction is one of the most effective interventions known for reducing cardiovascular event risk. Part of this effect may relate to weight loss, but direct renal and vascular GLP-1 receptor activity likely contributes independently.

Cardiac muscle effects

GLP-1 receptors are expressed in cardiac muscle cells. Early studies suggest GLP-1 receptor agonists may reduce myocardial inflammation and improve cardiac function after ischaemia. Whether these direct cardiac effects are clinically significant in humans remains an active area of investigation.

Why this changes the clinical picture

The conventional framing of GLP-1 medications - particularly Wegovy - positions them primarily as weight loss drugs. Insurance coverage, prescribing guidelines, and public understanding all centre on the BMI threshold and the weight number on the scale. The SELECT trial analysis challenges that framing at its foundation.

Professor Tim Chico of the University of Sheffield summarised the implication directly: the benefits of semaglutide "are not only caused by causing weight loss." This means restricting access based on BMI cutoffs or requiring a certain amount of weight loss before continuing treatment may not be medically justified for patients with cardiovascular disease.

Dr. Sonya Babu-Narayan of the British Heart Foundation added that the mechanisms behind the non-weight-related benefits - blood vessel health, blood pressure control, inflammation reduction - remain areas that need further investigation, but that the finding itself is clear: "Benefits go beyond weight loss alone."

For patients, the implication is direct. If you are taking semaglutide (Ozempic, Wegovy) and have existing heart disease, and you are losing weight more slowly than you hoped, the cardiovascular protection the drug is providing does not depend on the scale keeping pace. The drug is likely working on your arteries regardless of what the number shows.

What this does not mean

It is worth being precise about what this analysis does not claim:

  • It does not mean weight loss is unimportant. The 33% of benefit that is mediated by adiposity reduction is real and meaningful - losing weight does reduce cardiovascular risk.
  • It does not apply to people without cardiovascular disease. SELECT enrolled patients who already had heart disease. Whether the same mechanisms apply preventively in people with no cardiac history is a separate question.
  • It does not apply to tirzepatide (Mounjaro, Zepbound) directly - though tirzepatide activates GLP-1 receptors by the same mechanism, its dedicated cardiovascular outcome trial (SURPASS-CVOT) data are still accumulating.
  • The study population skewed male and did not fully represent women or all ethnic groups - a limitation the investigators acknowledged explicitly.

Nutrients that support cardiovascular health on GLP-1 therapy

For people taking semaglutide with a focus on heart health, one underappreciated issue is the nutritional impact of the medication. Significantly reduced food intake - a consistent feature of GLP-1 therapy - can deplete several micronutrients with direct roles in cardiovascular function:

  • Magnesium: involved in cardiac rhythm regulation, blood pressure control, and vascular smooth muscle relaxation. Deficiency is common on reduced-calorie diets and is associated with increased cardiovascular risk.
  • Vitamin D: a 2026 Harvard Health meta-analysis of 480,825 adults found 13.6% of GLP-1 users were deficient. Vitamin D deficiency is independently associated with increased cardiovascular risk and inflammation.
  • Omega-3 fatty acids: reduce triglycerides and have anti-inflammatory cardiovascular effects. Reduced fish and nut intake on appetite-suppressed diets can lower omega-3 status.
  • Vitamin B12: reduced gastric acid on long-term semaglutide therapy impairs B12 absorption. Deficiency causes elevated homocysteine, a recognised cardiovascular risk factor.

Maintaining adequate levels of these nutrients while on GLP-1 therapy is not just about general wellbeing - it may be specifically relevant to the cardiovascular outcomes people on these medications are working toward. GLP-1 Shield was formulated to address exactly these nutritional gaps for people on GLP-1 medications.

Worried about your own nutrient gaps on GLP-1?

Be among the first to try the scientifically designed GLP-1 Shield supplements.

Frequently asked questions

Does semaglutide protect the heart even if you don't lose much weight?
Yes - the SELECT trial prespecified analysis found that semaglutide's 20% reduction in major cardiac events was consistent across all levels of weight loss and across all baseline body sizes. Only about one-third of the cardiovascular benefit was explained by changes in waist circumference, meaning the majority of heart protection comes through mechanisms independent of fat loss.
What is the SELECT trial and what did it find?
SELECT was a randomised controlled trial of 17,604 adults with overweight or obesity and pre-existing cardiovascular disease (but no diabetes), comparing weekly semaglutide 2.4 mg to placebo over roughly four years. Semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% relative to placebo. A prespecified analysis published in The Lancet in October 2025 showed this benefit held regardless of how much weight participants lost.
How does semaglutide protect the heart beyond weight loss?
Proposed mechanisms include reduced systemic inflammation, direct effects on arterial endothelial function (improving blood vessel flexibility), modest blood pressure reduction, and possible direct effects on cardiac muscle via GLP-1 receptors expressed in heart tissue. Which of these mechanisms contributes most to the observed outcomes is still being investigated.
Should people with heart disease take Ozempic even if they are not obese?
The SELECT trial enrolled people with a BMI of at least 27 kg/m², which includes overweight but not people with a normal BMI. The trial's findings apply to that population specifically. Prescribing decisions for individual patients should be made with a cardiologist or specialist who can weigh trial eligibility criteria against individual clinical circumstances.